Oral treatment of companion animals with ectoparasiticidal spinosyns
AssigneeEli Lilly and Company
InventorDaniel Earl Snyder
Life of this patent
Estimating the term…
Abstract
The invention provides single-dose oral formulations for controlling an ectoparasite infestation on a companion animal for a prolonged time, said formulations comprising a spinosyn component, or a physiologically acceptable derivative or salt thereof, and a carrier in oral dosage form. It also provides methods for controlling such infestations comprising orally administering a single dose of these formulations to the animal.
Claims7
A single-dose oral formulation for controlling an ectoparasite infestation on a dog or cat comprising an ectoparasiticidal amount of spinosad, or a physiologically acceptable derivative or salt thereof, and a physiologically acceptable carrier in a systemically effective oral dosage form selected from tablet, capsule or liquid suitable for administration once every at least 7 days at a dose of 10 to 100 mg of spinosad per kg of body weight.
A single-dose oral formulation for controlling an ectoparasite infestation on a dog or cat comprising an ectoparasiticidal amount of spinosad, or a physiologically acceptable derivative or salt thereof, and a physiologically acceptable carrier in a systemically effective chewable treat oral dosage form suitable for administration once every at least 7 days at a dose of 10 to 100 mg of spinosad per kg of body weight.
Dependencies are inferred from the claim text.